Repurposing Fenofibrate for Early Diabetic Retinopathy: A Systemic and Disease-Modifying Approach

Diabetic retinopathy (DR) remains a major cause of blindness worldwide, highlighting the need for accessible treatments that prevent its onset and progression. This review explores the potential of repurposing fenofibrate, a traditional lipid-lowering drug, as a systemic, disease-modifying therapy for DR.

This narrative synthesis of clinical and molecular studies was conducted to evaluate therapeutic impact of fenofibrate on DR. Evidence from trials was integrated with recent mechanistic data to clarify lipid-independent pathways of fenofibrate in retinal protection.

Fenofibrate significantly reduced the progression of DR independent of serum lipid levels. Mechanistic insights indicate both PPAR-α-dependent and -independent actions that collectively protect retinal microvasculature. These include suppression of inflammation, reduction of oxidative stress, enhancement of endothelial function, and preservation of blood-retinal barrier integrity. The convergence of clinical and molecular evidence suggests that fenofibrate may exert direct retinal benefits beyond its metabolic effects.

Fenofibrate represents a practical, systemic therapy capable of halting early DR progression. By targeting underlying pathogenic mechanisms, it offers a preventative approach that complements current late-stage ocular interventions and may reduce the global burden of diabetes-related vision loss.